vs
Side-by-side financial comparison of Can-Fite BioPharma Ltd. (CANF) and Pasithea Therapeutics Corp. (KTTA). Click either name above to swap in a different company.
Pasithea Therapeutics Corp. is the larger business by last-quarter revenue ($240.7K vs $202.0K, roughly 1.2× Can-Fite BioPharma Ltd.). Pasithea Therapeutics Corp. runs the higher net margin — -2126.1% vs -2413.9%, a 287.8% gap on every dollar of revenue. Pasithea Therapeutics Corp. produced more free cash flow last quarter ($-4.5M vs $-4.8M).
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing proprietary small molecule therapeutics targeting adenosine receptors. Its product pipeline addresses unmet medical needs across oncology, inflammatory diseases, and liver disorders, with operations serving global healthcare markets and research partnership networks worldwide.
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.
CANF vs KTTA — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2022
| Metric | | |
|---|---|---|
| Revenue | $202.0K | $240.7K |
| Net Profit | $-4.9M | $-5.1M |
| Gross Margin | — | — |
| Operating Margin | -2424.8% | -1679.5% |
| Net Margin | -2413.9% | -2126.1% |
| Revenue YoY | -36.1% | — |
| Net Profit YoY | -23.2% | — |
| EPS (diluted) | $0.00 | $-1.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $202.0K | — | ||
| Q2 24 | $316.0K | — | ||
| Q4 22 | — | $240.7K | ||
| Q3 22 | — | $218.6K | ||
| Q2 22 | — | $13.6K | ||
| Q1 22 | — | $13.7K |
| Q2 25 | $-4.9M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q4 22 | — | $-5.1M | ||
| Q3 22 | — | $-4.6M | ||
| Q2 22 | — | $-2.7M | ||
| Q1 22 | — | $-1.6M |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | 60.4% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | 5.3% |
| Q2 25 | -2424.8% | — | ||
| Q2 24 | -1295.6% | — | ||
| Q4 22 | — | -1679.5% | ||
| Q3 22 | — | -1763.8% | ||
| Q2 22 | — | -19229.5% | ||
| Q1 22 | — | -15221.0% |
| Q2 25 | -2413.9% | — | ||
| Q2 24 | -1252.2% | — | ||
| Q4 22 | — | -2126.1% | ||
| Q3 22 | — | -2097.9% | ||
| Q2 22 | — | -19574.4% | ||
| Q1 22 | — | -11526.1% |
| Q2 25 | $0.00 | — | ||
| Q2 24 | $0.00 | — | ||
| Q4 22 | — | $-1.72 | ||
| Q3 22 | — | $-0.01 | ||
| Q2 22 | — | $-0.02 | ||
| Q1 22 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.5M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $42.5M |
| Total Assets | $7.7M | $45.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $6.5M | — | ||
| Q2 24 | $4.7M | — | ||
| Q4 22 | — | $33.1M | ||
| Q3 22 | — | $42.4M | ||
| Q2 22 | — | $47.9M | ||
| Q1 22 | — | $50.3M |
| Q2 25 | $4.2M | — | ||
| Q2 24 | $2.5M | — | ||
| Q4 22 | — | $42.5M | ||
| Q3 22 | — | $46.8M | ||
| Q2 22 | — | $51.3M | ||
| Q1 22 | — | $50.0M |
| Q2 25 | $7.7M | — | ||
| Q2 24 | $5.9M | — | ||
| Q4 22 | — | $45.2M | ||
| Q3 22 | — | $49.6M | ||
| Q2 22 | — | $53.0M | ||
| Q1 22 | — | $51.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-4.4M |
| Free Cash FlowOCF − Capex | $-4.8M | $-4.5M |
| FCF MarginFCF / Revenue | -2353.0% | -1874.2% |
| Capex IntensityCapex / Revenue | 0.5% | 38.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-4.8M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q4 22 | — | $-4.4M | ||
| Q3 22 | — | $-5.2M | ||
| Q2 22 | — | $-2.4M | ||
| Q1 22 | — | $-2.5M |
| Q2 25 | $-4.8M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q4 22 | — | $-4.5M | ||
| Q3 22 | — | $-5.2M | ||
| Q2 22 | — | $-2.4M | ||
| Q1 22 | — | $-2.5M |
| Q2 25 | -2353.0% | — | ||
| Q2 24 | -1278.5% | — | ||
| Q4 22 | — | -1874.2% | ||
| Q3 22 | — | -2398.9% | ||
| Q2 22 | — | -17553.7% | ||
| Q1 22 | — | -18519.8% |
| Q2 25 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q4 22 | — | 38.5% | ||
| Q3 22 | — | 2.5% | ||
| Q2 22 | — | 51.1% | ||
| Q1 22 | — | 14.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
